CLEVELAND, April 23, 2019 /PRNewswire/ -- ViewRay, Inc.
(Nasdaq: VRAY) announced today that the company's MRIdian
MRI-guided radiation therapy system will be featured at the Annual
Meeting of the European Society for Radiotherapy and Oncology
(ESTRO), with a number of presentations and posters highlighting
MRIdian research and clinical experience. The ESTRO meeting will be
held April 26-30 in Milan, Italy.
MRIdian MRI-guided radiation therapy offers continuous,
high-quality soft tissue visualization and automated beam-gating to
improve the accuracy and precision of cancer treatment. The
significant interest around MRIdian is reflected in more than 25
MRIdian presentations and posters accepted as part of ESTRO's
Scientific Sessions. These abstracts were submitted by MRIdian
users from around the world.
MRIdian Scientific Session presentations and posters will focus
on clinical experience, patient outcomes, and response assessment
and prediction, along with physics topics such as intra-fraction
motion, commissioning and quality assurance. These presentations
and posters will cover a wide array of clinical applications such
as lung, pancreatic, cervical, breast, spinal, pelvic,
abdominal, adrenal, and rectal cancers. The accepted MRIdian
abstracts include clinical data from more than 150 patients and a
significant number highlight MRIdian's adaptive therapy
capabilities.
First pioneered by ViewRay in 2012, MRI-guided real-time
on-table adaptive radiotherapy (MRI-Guided ROAR) represents a new
paradigm in cancer treatment. It provides clinicians with the
ability to improve targeting precision and accuracy to deliver
higher, and potentially more effective, radiation doses.
ViewRay will host a Symposium on MRI-Guided ROAR on Sunday, April 28 from 1:15- 2:15 p.m. in Amber 8 Meeting Room. The
symposium will highlight clinical experience with on-table adaptive
therapy at both new and veteran MRIdian centers, with presentations
by Enis Özyar, M.D., from Acibadem Maslak Hospital on the rapid
introduction of on-table adaptive at their new MRIdian site, and by
Miguel Palacios, medical physicist
at Amsterdam University Medical Centers on their three years of
MRIdian on-table adaptive therapy experience.
Visitors to ViewRay's booth #350 can hear first-hand MRIdian
experience from clinicians at Gemelli ART/Università Cattolica del
Sacro Cuore, Washington University
School of Medicine, Acibadem Maslak Hospital, Institut
Paoli-Calmettes Marseille and Heidelberg University Hospital.
Featured topics include extracting info from MR images, prospective
clinical trials, adaptive radiotherapy workflows, patient-specific
QA, dosimetric properties and Monte
Carlo model for the RayZR doublestack MLC, and the overall
investment rationale.
Please visit https://go.viewray.com/ESTRO_2019 for a detailed
schedule of MRIdian presentations, posters and in-booth
speakers.
About ViewRay
ViewRay®, Inc. (Nasdaq: VRAY), designs,
manufactures and markets the MRIdian® radiation therapy system.
MRIdian is built upon a proprietary high-definition MR imaging
system designed from the ground up to address the unique challenges
and clinical workflow for advanced radiation oncology. Unlike MR
systems used in diagnostic radiology, MRIdian's high-definition MR
was purposely built to deliver high-precision radiation without
unnecessary beam distortion, and consequently, help to mitigate
skin toxicity and other safety concerns that may otherwise arise
when high magnetic fields interact with radiation beams. ViewRay
and MRIdian are registered trademarks of ViewRay, Inc.
Intended Use: The MRIdian Linac System, with
magnetic resonance imaging capabilities, is intended to provide
stereotactic radiosurgery and precision radiotherapy for lesions,
tumors, and conditions anywhere in the body where radiation
treatment is indicated.
Forward-Looking Statements: This press release
contains forward-looking statements. Statements in this press
release that are not purely historical are forward-looking
statements. These statements are subject to risks and uncertainties
that could cause future results to differ materially from those
referenced. Forward looking statements include, but are not limited
to references to future MRIdian experience, clinical value and
outcomes. Given these uncertainties, the reader is advised not to
place any undue reliance on any forward-looking statements.
Additional risk factors include, among others, the ability to raise
the additional funding needed to continue to pursue ViewRay's
business and product development plans, the inherent uncertainties
associated with developing new products or technologies,
competition in the industry in which ViewRay operates, government
and regulatory uncertainty, including but not limited to obtaining
authorizations to market and new tariffs and trade restrictions,
and overall market conditions. These forward-looking statements are
made as of the date of this press release, and ViewRay assumes no
obligation to update the forward-looking statements, or to update
the reasons why actual results differ from those projected in the
forward-looking statements, except as required by law. Investors
should consult all of the information set forth herein and should
also refer to the risk factor disclosure set forth in the reports
and other documents ViewRay files with the SEC available at
www.sec.gov.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/viewrays-mridian-to-be-featured-at-leading-european-radiation-oncology-meeting-300836033.html
SOURCE ViewRay, Inc.